Synergistic interactions between peloruside A and other microtubule-stabilizing and destabilizing agents in cultured human ovarian carcinoma cells and murine T cells

Cancer Chemotherapy and Pharmacology

Volumn 68, Issue 1, 2011, Pages 117-126

  Wilmes, Anja ^a   O'Sullivan, David ^a   Chan, Ariane ^a   Chandrahasen, Clarissa ^a   Paterson, Ian ^b   Northcote, Peter T ^a   Flamme, Anne Camille La ^a   Miller, John H ^a  

^a VICTORIA UNIVERSITY OF WELLINGTON   (New Zealand)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Anticancer drug; Combination therapy; Laulimalide; Microtubule targeting agent; Peloruside A; Synergy

Indexed keywords

2 METHOXYESTRADIOL; ANTINEOPLASTIC AGENT; DISCODERMOLIDE; DOCETAXEL; EPOTHILONE A; IXABEPILONE; LAULIMALIDE; PACLITAXEL; PELORUSIDE A; UNCLASSIFIED DRUG; VINBLASTINE;

ANIMAL CELL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CARCINOMA CELL; CD4+ T LYMPHOCYTE; CELL STRAIN 1A9; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BINDING; DRUG BINDING SITE; DRUG POTENTIATION; DRUG RESPONSE; FEMALE; HUMAN; HUMAN CELL; IC 50; MICROTUBULE; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE;

ANIMALS; BICYCLO COMPOUNDS, HETEROCYCLIC; CELL LINE, TUMOR; CELL PROLIFERATION; CELLS, CULTURED; DRUG SYNERGISM; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; LACTONES; MACROLIDES; MICE; MICE, INBRED C57BL; MICROTUBULES; OVARIAN NEOPLASMS; SPLEEN; T-LYMPHOCYTES; TUBULIN MODULATORS;

EID: 79959597439     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-010-1461-3     Document Type: Article

References (38)

1. Belani CP, Ramalingam S, Perry MC, LaRocca RV, Rinaldi D, Gable PS, Tester WJ (2008) Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer. J Clin Oncol 26:468-473 (Pubitemid 351171701)
2. Berenbaum MC (1985) The expected effect of a combination of agents: the general solution. J Theor Biol 114:413-431
3. Blansfield JA, Caragacianu D, Alexander HR III, Tangrea MA, Morita SY, Lorang D, Schafer P, Muller G, Stirling D, Royal RE, Libutti SK (2008) Combining agents that target the tumor microenvironment improves the efficacy of anticancer therapy. Clin Cancer Res 14:270-280 (Pubitemid 351384377)
4. Brunden KR, Trojanowski JQ, Lee VM (2009) Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies. Nat Rev Drug Discov 8:783-793
5. Budman DR, Calabro A (2002) In vitro search for synergy and antagonism: evaluation of docetaxel combinations in breast cancer cell lines. Breast Cancer Res Treat 74:41-46
6. Campone M, Blasinska-Morawiek M, Tekiela A, Koralewski P, Pouget JC, Douville I, Brandely M (2009) Phase II study of vinerelbine (alternating intravenous and oral) in combination with docetaxel as first-line chemotherapy in metastatic breast cancer. Cancer Chemother Pharmacol 63:937-943
7. Chan A, Andreae P, Northcote PT, Miller JH (2010) Peloruside A inhibits microtubule dynamics in a breast cancer cell line MCF7. Invest New Drugs. doi:10.1007/s10637-010-9398-2
8. Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27-55
9. Clark EA, Hills PM, Davidson BS, Wender PA, Mooberry SL (2006) Laulimalide and synthetic laulilmalide analogues are synergistic with paclitaxel and 2-methoxyestradiol. Mol Pharm 3:457-467 (Pubitemid 44351929)
10. Crume KP, Miller JH, La FlammeAC (2007) Peloruside A, an antimitotic agent, specifically decreases TNF-a production by LPS-stimulated murine macrophages. Exp Biol Med 232:607-613 (Pubitemid 46683385)
11. Crume KP, O'Sullivan D, Miller JH, Northcote PT, La Flamme AC (2009) Delaying the onset of experimental autoimmune encephalomyelitis with the microtubule-stabilizing compounds, paclitaxel and peloruside A. J Leukoc Biol 86:949-958
12. Delord JP, Dalenc F, Pinguet F, Nguyen L, Lochon I, Poublanc M, Chatelut E, Roche H (2007) A phase I-escalating and pharmacokinetic study of docetaxel and vinorelbine as first-line chemotherapy for metastatic breast cancer. Oncology 72:322-325 (Pubitemid 351238144)
13. Edelmann JM (2009) Novel taxane formulations and microtubule-binding agents in non-small-cell lung cancer. Clin Lung Cancer 10:30-34
14. Gaitanos TN, Buey RM, Díaz JF, Northcote PT, Teesdale-Spittle P, Andreu JM, Miller JH (2004) Peloruside A does not bind to the taxoid site on β-tubulin and retains its activity in multidrug-resistant cell lines. Cancer Res 64:5063-5067 (Pubitemid 39006519)
15. Gapud EJ, Bai R, Ghosh AK, Hamel E (2004) Laulimalide and paclitaxel: a comparison of their effects on tubulin assembly and their synergistic action when present simultaneously. Mol Pharmacol 66:113-121 (Pubitemid 38822093)
16. Gertsch J, Meier S, Müller M, Altmann KH (2009) Differential effects of natural product microtubule stabilizers on microtubule assembly: Single agent and combination studies with Taxol, epothilone B, and discodermolide. Chem Biol Chem 10:166-175
17. Giannakakou P, Fojo T (2000) Discodermolide: just another microtubule-stabilizing agent? No! A lesson in synergy. Clin Cancer Res 6:1613-1615 (Pubitemid 30305051)
18. Giannakakou P, Villalba L, Li H, Poruchynsky M, Fojo T (1998) Combinations of paclitaxel and vinblastine and their effects on tubulin polymerization and cellular cytotoxicity: characterization of a synergistic schedule. Int J Cancer 75:57-63 (Pubitemid 28113978)
19. Hamel E, Day BW, Miller JH, Jung MK, Northcote PT, Ghosh AK, Curran DP, Cushman M, Nicolaou KC, Paterson I, Sorensen EJ (2006) Synergistic effects of peloruside A and laulimalide with taxoid site drugs, but not with each other, on tubulin assembly. Mol Pharmacol 70:1555-1564
20. Han G-Z, Liu Z-J, Shimoi K, Zhu BT (2005) Synergism between the anticancer actions of 2-methoxyestradiol and microtubule-disrupting agents in human breast cancer. Cancer Res 65:387-393
21. Honore S, Kamath K, Braguer D, Horwitz SB, Wilson L, Brian C, Jordan MA (2004) Synergistic suppression of microtubule dynamics by discodermolide and paclitaxel in non-small cell lung carcinoma cells. Cancer Res 64:4957-4964 (Pubitemid 38924543)
22. Huang GS, Lopez-Barcons L, Freeze BS, Smith AB III, Goldberg GL, Horwitz SB, McDaid HM (2006) Potentiation of Taxol efficacy by discodermolide in ovarian carcinoma xenograft-bearing mice. Clin Cancer Res 12:298-304 (Pubitemid 43166207)
23. Huzil JT, Chik JK, Slysz GW, Freedman H, Tuszynski J, Taylor RE, Sackett DL, Schriemer DC (2008) A unique mode of microtubule stabilization induced by peloruside A. J Mol Biol 378:1016-1030
24. Jordan MA, Wilson L (2004) Microtubules as a target for anticancer drugs. Nat Rev Cancer 4:253-265 (Pubitemid 38525281)
25. Khrapunovich-Baine M, Menon V, Verdier-Pinard P, Smith AB III, Angeletti RH, Fiser A, Horwitz SB, Xiao H (2009) Distinct pose of discodermolide in Taxol binding pocket drives a complementary mode of microtubule stabilization. Biochemistry 48:11664-11677
26. Lee FY, Borzilleri R, Fairchild CR, Kim SH, Long BH, Reventos-Suarez C, Vite GD, Rose WC, Kramer RA (2001) BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res 7:1429-1437 (Pubitemid 32708699)
27. Martello LA, McDaid HM, Regl DL, Yang CP, Meng D, Pettus TR, Kaufman MD, Arimoto H, Danishefsky SJ, Smith AB III, Horwitz SB (2000) Taxol and discodermolide represent a synergistic drug combination in human carcinoma cell lines. Clin Cancer Res 6:1978-1987 (Pubitemid 30305097)
28. Miller JH, Singh AJ, Northcote PT (2010) Microtubule-stabilizing drugs from marine sponges: focus on peloruside and zampanolide. Mar Drugs 8:1059-1079
29. Miller VA (1997) Docetaxel (Taxotere) and vinorelbine in the treatment of advanced non-small cell lung cancer: preliminary results of a phase I/II trial. Semin Oncol 24(Suppl 14):S14-15-S14-17
30. Okuda K, Hirose T, Ishida H, Kusumoto S, Sugiyama T, Ando K, Ohnishi T, Horichi N, Ohmori T, Adachi M (2008) Phase I study of the combination of nedaplatin and weekly paclitaxel in patients with advanced non-small cell lung cancer. Cancer Chemother Pharmacol 61:829-835 (Pubitemid 351302039)
31. Paterson I, Florence GJ, Gerlach K, Scott JP, Sereinig N (2001) A practical synthesis of (?)-discodermolide and analogues: Fragment union by complex aldol reactions. J Am Chem Soc 123:9535-9544 (Pubitemid 32937726)
32. Photiou A, Shah P, Leong LK, Moss J, Retsas S (1997) In vitro synergy of paclitaxel (Taxol) and vinorelbine (navelbine) against human melanoma cell lines. Eur J Cancer 33:463-470
33. Pryor DE, O'Brate A, Bilcer G, Díaz JF, Wang Y, Wang Y, Kabaki M, Jung MK, Andreu JM, Ghosh AK, Giannakakou P, Hamel E (2002) The microtubule stabilizing agent laulimalide does not bind in the taxoid site, kills cells resistant to paclitaxel and epothilones, and may not require its epoxide moiety for activity. Biochemistry 41:9109-9115 (Pubitemid 34787268)
34. Robinson MJ, Ronchese F, Miller JH, La Flamme AC (2009) Paclitaxel inhibits killing by murine cytotoxic T lymphocytes in vivo but not in vitro. Immunol Cell Biol 88:291-296
35. Rowinsky EK, Donehower RC (1995) Paclitaxel (Taxol). N Engl J Med 332:1004-1014
36. West LM, Northcote PT, Battershill CN (2000) Peloruside A: a potent cytotoxic macrolide isolated from the New Zealand marine sponge Mycale sp. J Org Chem 65:445-449 (Pubitemid 30061125)
37. Wilmes A, Bargh K, Kelly C, Northcote PT, Miller JH (2007) Peloruside A synergizes with other microtubule stabilizing agents in cultured cancer cell lines. Mol Pharm 4:269-280 (Pubitemid 46640603)
38. Wilmes A, Rawson P, Peng L, McLauchlan D, Northcote PT, Jordan TW, Miller JH (2010) Effects of the microtubule stabilizing agent peloruside A on the proteome of HL-60 cells. Invest New Drugs. doi:10.1007/s10637-010-9387-5